FDA label
What is Incruse Ellipta used for?
Incruse Ellipta contains umeclidinium bromide. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Incruse Ellipta?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Incruse Ellipta, aerosol, powder
Indications and Usage, quoted from the label by GlaxoSmithKline LLC (NDA205382). Cross-references to other label sections are left out.
INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Source: DailyMed label, set id dbb64747-1505-49d7-9a33-99dd402e96d3, version 27, effective December 13, 2023. NDC 0173-0873, one of 1 listing for this product.
Questions
What is Incruse Ellipta used for?
The FDA label says: “INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
What drug class is Incruse Ellipta?
FDA lists umeclidinium bromide in the Anticholinergic established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.